SWOG clinical trial number
CTSU/R9804

Phase III Trial of Tamoxifen Alone vs. Tamoxifen plus RT for Good Risk Duct Carcinoma in Situ (DCIS) of the Female Breast

Closed
Phase
Abbreviated Title
Adjuvant - DCIS
Activated
06/15/2001
Closed
07/14/2006
Participants
CTSU

Research committees

Breast Cancer

Treatment

Tamoxifen Radiation Therapy RT

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group participated in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information.

Publication Information Expand/Collapse

2021

Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804

B McCormick;K Winter;W Woodward;H Kuerer;N Sneige;E Kakovitch;B Smith;I Germain;A Hartford;M O'Rourke;E Walker;E Strom;J Hopkins;L Pierce;A Pu;K Sumida;D Vesprini;J Moughan;J White Journal of Clinical Oncology, Nov 10;39(32):3574-3582

PMid: PMID34406870 | PMC number: PMC8577682

2014

Web based pathology assessment in RTOG 98-04

WA Woodward;N Sneige;K Winter;HM Kuerer;C Hudis;E Rakovitch;BL Smith;LJ Pierce;I Germano;AT Pu;EM Walker;DL Grisell;JR White;B McCormick Journal of Clinical Pathology 67(9):777-780;

PMid: PMID24989024 | PMC number: PMC4145412

Other Clinical Trials

SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
3%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase